Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$3.91 AUD
Change Today -0.03 / -0.76%
Volume 197.1K
MSB On Other Exchanges
As of 2:10 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

mesoblast ltd (MSB) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/14 - A$5.88
52 Week Low
04/10/15 - A$3.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MESOBLAST LTD (MSB)

Related News

No related news articles were found.

mesoblast ltd (MSB) Details

Mesoblast Limited, a biotechnology company, is engaged in the research and development of its propriety stem cell technologies for use in the treatment of multiple major disease states and other medical conditions. The company’s cell-based core technologies include immunoselected mesenchymal precursor cells (MPCs), culture-expanded mesenchymal stem cells (MSCs), dental pulp stem cells, and expanded hematopoietic stem cells. Its lead products include MSC-100-IV, which is used for the treatment of steroid refractory acute graft versus host disease and biologic refractory crohn’s disease; MPC-06-ID that is used for the treatment of chronic low back pain; and MPC-150-IM, which is used for congestive heart failure treatment. The company also offers supporting products, such as MPC-300-IV, an intravenously administered MPCs that are used for the treatment of type 2 diabetes, liver/kidney complications, and rheumatoid arthritis; MPC-25-IC, which is used for the treatment of acute myocardial infarction; MPC-25-Osteo for use in surgical bone repair; MPC-CBE that is used in bone marrow transplantations; and MPC-MICRO-IO for use in age-related macular degeneration treatment. In addition, it provides various products for the treatment of ophthalmology diseases, neurological diseases, lung diseases, etc. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf (allogeneic) adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its immunoselected MPCs that are used for cardiac and vascular diseases. It has operations in Australia, the United States, and Singapore. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

115 Employees
Last Reported Date: 08/25/14
Founded in 2004

mesoblast ltd (MSB) Top Compensated Officers

Chief Executive Officer, Founder, Managing Di...
Total Annual Compensation: A$1.8M
Compensation as of Fiscal Year 2014.

mesoblast ltd (MSB) Key Developments

Mesoblast Limited Announces Results of Phase 2 Trial of Its Intravenously-Delivered Mesenchymal Precursor Cells

Mesoblast Limited announced that results of the Phase 2 trial of its intravenously-delivered Mesenchymal Precursor Cells (MPCs) for the treatment of type 2 diabetes have been published online ahead of full print in the peer-reviewed journal of the American Diabetes Association, Diabetes Care. Type 2 diabetes is associated with aberrant immune activation and inflammation of various organs, including kidney, liver and fat tissues, resulting in resistance to the effects of insulin in the fat tissues, and poor glucose control. The most frequent end-organ complication involves the kidney, a condition termed diabetic nephropathy, which affects 40-50% of patients with type 2 diabetes. Mesoblast's product candidate MPC-300-IV is being developed to treat systemic conditions of excessive inflammation, including type 2 diabetes and its complications, by down-regulating the production of pro-inflammatory cytokines and increasing the production of anti-inflammatory cytokines. As a first step in developing an MPC-based immunomodulatory therapy for the treatment of type 2 diabetes and its complications, a study was performed which evaluated three escalating doses in patients with type 2 diabetes and poor glycemic control, without kidney disease or other organ involvement. The Phase 2 randomized, single-blind, placebo-controlled trial was conducted across 18 sites in the United States and evaluated the effects of a single intravenous infusion of 0.3, 1.0 or 2.0 million MPCs/kilogram (kg) or placebo over 12 weeks in 61 patients with a mean diabetes duration of 10 years. The primary objective of the study was to assess the safety and tolerability of a single intravenous infusion of Mesoblast's MPC therapy (rexlemestrocel-L) in patients with type 2 diabetes. Secondary objectives included evaluation of treatment effect on glycemic control, defined by hemoglobin A1c (HbA1c) measurement, the gold-standard measure of long-term blood sugar control. Key findings were: Primary endpoint of safety: A single MPC infusion ranging from 0.3 to 2.0 million MPCs/kg was safe and well tolerated, with no treatment-related adverse events, and no serious adverse events over the 12-week study period. There were no anti-human leukocyte antigen antibody immune responses against MPC donor antigens identified in any subject. Secondary efficacy endpoints: Following a single intravenous MPC infusion, there was an improvement in glycemic control as evidenced by a decrease at all timepoints after week 1 in HbA1c in MPC-treated patients compared with an increase in HbA1c in placebo-controlled patients. The high dose (2.0 million MPCs/kg) showed the great overall reduction in HbA1c, with a peak decrease of 0.4% at 8 weeks compared with placebo (p less than 0.05). In the less well-controlled subjects, as defined by a baseline HbA1c greater than 8.0%, a 0.6% decrease in HbA1c was seen at 8 weeks in the high dose cohort compared with placebo. The clinical target of good glycemic control, HbA1c less than 7%, was achieved by 5/15 (33%) subjects in the MPC 2.0 million/kg group vs. 0/15 (0%) in the placebo group, (p less than 0.05).

Mesoblast Limited Announces Phase 2 Trial Results of Cell Therapy Product Candidate for the Treatment of Congestive Heart Failure

Mesoblast Limited announced that Phase 2 trial results of its cell therapy product candidate for the treatment of congestive heart failure have been published in the latest edition of Circulation Research. The results were published as an 'online first' article ahead of full print in this peer-reviewed, high-impact journal of the American Heart Association. Patients with advanced heart failure have a poor long-term prognosis and few therapeutic options. Mesoblast's proprietary Mesenchymal Precursor Cells (MPCs) may offer a promising alternative because of their ability to induce heart muscle repair, stimulate new blood vessel growth, decrease cell death and reduce scar formation. In the article, entitled 'A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Non-Ischemic Heart Failure', the authors concluded that high-dose allogeneic MPC treatment may reduce heart failure-related major adverse cardiovascular events (HF-MACE) and provide beneficial effects on adverse left ventricular remodelling.

Mesoblast Limited Announces Results from the Phase 2 Trial in Patients with Diabetic Nephropathy

Mesoblast Limited announced that results from the company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks. MPC-300-IV was evaluated in a double-blind, randomized, placebo-controlled, dose-escalating Phase 2 trial of 30 patients with type 2 diabetes and moderate to severe renal impairment, stage 3b-4 chronic kidney disease (CKD), who were already on a stable regimen of the standard of care therapy for diabetic nephropathy (renin-angiotensin system inhibition with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers). Patients received a single infusion of 150 million MPCs, 300 million MPCs, or saline control. The objectives of the trial were to evaluate safety and to explore potential efficacy signals of MPC treatment on renal function. The pre-specified primary efficacy endpoint was to evaluate effects of MPC treatment relative to placebo on renal functional decline at 12 weeks, as defined by change in glomerular filtration rate (GFR) measured both by direct isotope scan and by serum-creatinine based estimation, and then for an additional 48 weeks of follow-up. Pre-specified secondary analyses included GFR differences between treatment and placebo groups with baseline GFR greater than 30ml/min/1.73m2 (stage 3b CKD, accounting for 60% of enrolled patients), and treatment-related effects on the monocyte-derived cytokine interleukin-6 (IL-6), a major inflammatory marker associated with renal failure progression and adverse cardiovascular outcomes. The primary efficacy endpoint of decline or change in GFR was in line with the 2012 joint workshop held by the United States Food and Drug Administration and the National Kidney Foundation which recommended that time to 30-40% decline in GFR is an acceptable primary endpoint for evaluating potential benefits of new therapies for this patient population (Levey et al. GFR decline as an endpoint in clinical trials for CKD.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSB:AU A$3.91 AUD -0.03

MSB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.14 USD -0.025
Caladrius Biosciences Inc $1.53 USD -0.125
Celyad €51.50 EUR +1.01
Pluristem Therapeutics Inc $2.34 USD -0.05
Vericel Corp $3.45 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation MSB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.5x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 32.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MESOBLAST LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at